Patent intelligence · CA
CA 2849366
COMPOSITIONS ET PROCEDES POUR TRAITER LA PRESBYTIE, L'HYPERMETROPIE LEGERE ET L'ASTIGMATISME IRREGULIER
COMPOSITIONS ET PROCEDES POUR TRAITER LA PRESBYTIE, L'HYPERMETROPIE LEGERE ET L'ASTIGMATISME IRREGULIER
Patent details — CA 2849366
- Jurisdiction
- CA
- Status
- granted
- Grant date
- Mar 28, 2013
- Expiration
- Mar 23, 2033
- Applicant
- ALLERGEN INC [US]
- CPC classes
- A61K 31/ 27 A I, A61K 31/ 4164 A I, A61K 31/ 4174 A I, A61K 31/ 4178 A I
Quick answer
CA 2849366 (COMPOSITIONS ET PROCEDES POUR TRAITER LA PRESBYTIE, L'HYPERMETROPIE LEGERE ET L'ASTIGMATISME IRREGULIER) is held by ALLERGEN INC [US]. Status: granted. Granted Mar 28, 2013. Expires Mar 23, 2033 (7 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- ALLERGEN INC [US]
- Grant date
- Expiration
- Claims
- —
- CPC classes
- A61K 31/ 27 A I, A61K 31/ 4164 A I, A61K 31/ 4174 A I, A61K 31/ 4178 A I, A61K 31/ 5415 A I, A61K 45/ 06 A I
More from ALLERGEN INC [US]
Related pharmaceutical patents in our USPTO index.
-
CN 112638413
Oral immunotherapy unit dose dispensing systems and methods
granted -
WO 2015187736
FORMULATIONS PLACEBO ET UTILISATIONS DE CELLES-CI
granted -
US 2014356438
PERIPHERALLY ADMINISTERED VISCOUS FORMULATIONS
granted -
US 2014271721
PEANUT FORMULATIONS AND USES THEREOF
granted -
US 2014271836
MANUFACTURE OF PEANUT FORMULATIONS FOR ORAL DESENSITIZATION
granted -
US 2013209398
CONDITIONED CELL CULTURE MEDIUM COMPOSITIONS AND METHODS OF USE
granted -
US 2012003230
SUSTAINED RELEASE DRUG DELIVERY SYSTEMS COMPRISING A WATER SOLUBLE THERAPEUTIC AGENT AND A RELEASE MODIFIER
granted
Frequently asked questions
What is US patent 2849366?
CA 2849366 (COMPOSITIONS ET PROCEDES POUR TRAITER LA PRESBYTIE, L'HYPERMETROPIE LEGERE ET L'ASTIGMATISME IRREGULIER) is held by ALLERGEN INC [US]. Status: granted. Granted Mar 28, 2013. Expires Mar 23, 2033 (7 years remaining) — relevant for patent-cliff and LOE planning.
Who owns CA 2849366?
ALLERGEN INC [US] is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 24 pharmaceutical patents for this assignee.
When does CA 2849366 expire?
Our index shows an expiration date of Mar 23, 2033 (7 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.